We stratified a total of 767 MM patients, for whom both RNA-seq data and clinical data were available, in high- versus low-expression groups based on the median cut-off value for either JAG1 or JAG2 expression level across the entire dataset. The gene discussed is JAG2; the disease is Miyoshi myopathy.